4D Molecular Therapeutics, Inc.

12d ago, source: CNN

4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of unlocking the full potential of genetic medicines to treat large market diseases in ...

4D Molecular Therapeutics new overweight at Barclays on genetic medicine platform

on MSN ago, source:

Barclays overweight rating on 4D Molecular Therapeutics highlights the validation of their AAV vector technology, with a $45 ...

RBC Capital Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)

3d ago, source:

In a report released today, Lisa Walter from RBC Capital reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research Report), ...

4D Molecular Therapeutics Outlines Pivotal Development Plans For Cystic Fibrosis, Rare Inherited Disease

21d ago, source: Hosted on MSN

4D Molecular Therapeutics Inc (NASDAQ:FDMT) announced an update on its 4D-710, an aerosolized genetic medicine for cystic fibrosis (CF) lung disease. CF is a genetic (inherited) disease that ...

4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares

20d ago, source: Yahoo Finance

Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics Inc (NASDAQ:FDMT), has sold 5,833 shares of the company on March 27, 2024, according to a recent SEC filing. The transaction was ...

4D Molecular Therapeutics Stock (NASDAQ:FDMT), Analyst Ratings, Price Targets, Predictions

17d ago, source: Benzinga.com

$26.35 36.62% HC Wainwright & Co.

4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares

14d ago, source: Yahoo Finance

On April 1, 2024, Chief Legal Officer Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics Inc (NASDAQ:FDMT) according to a recent SEC Filing. The transaction was executed at an average ...

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates

1mon ago, source: Nasdaq

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.84 per share a year ago.

4D Molecular Therapeutics, Inc.: 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis

21d ago, source: Finanznachrichten

March 28, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of ...

4D Molecular Therapeutics Inc Ordinary Shares

2d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

4D Molecular Therapeutics Inc.

2mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...